AbbVie Inc., et al.
The FTC filed a federal complaint against AbbVie Inc. and Besins Healthcare Inc. in 2014, alleging they illegally blocked generic competition to the testosterone replacement drug AndroGel through sham patent infringement litigation. A district court found liability and ordered $448 million in consumer relief, though the Third Circuit and subsequent Supreme Court precedent (AMG Capital Management v. FTC) reversed the monetary judgment. AbbVie and Teva were subjected to Commission orders barring certain reverse-payment settlements, and on July 30, 2021, the FTC withdrew its remaining reverse-payment claim, ending the litigation.
Required actions (2)
AbbVie and Teva are also now subject to Commission orders preventing them from entering into certain reverse-payment settlements.
On July 30, 2021, the Commission announced that it has withdrawn its reverse-payment claim from federal district court, ending its litigation against AbbVie.
Does your site contain similar claims?
The free site audit scans your whole site against every entry in this Atlas. Most trt sites match 3-6 patterns.
Run my free site auditWorried about one specific page, ad, or email? Paste it into the free Claim Checker and see what the FDA and FTC would flag, with the precedent next to each one. No email required.
Check specific copy in the Claim Checker